NEW YORK, Sept. 10, 2014 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Prosensa Holding N.V. ("Prosensa" or the "Company") (Nasdaq:RNA) common stock pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about June 28, 2013.
Click here to learn about the case: http://docs.wongesq.com/RNA-Info-Request-Form-362. There is no cost or obligation to you.
The complaint alleges that the Registration Statement contained materially false and/or misleading statements and/or omitted material information concerning the development status of the drug drisapersen, the drug's Phase II and Phase III clinical studies, and its prospects for regulatory approval.
On September 20, 2013, the Company issued a press release disclosing that the drug had not met the primary endpoint in the Phase III study. Following this news, Prosensa stock declined approximately 70 percent, or $16.86 per share.
If you suffered a loss in Prosensa you have until September 16, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/RNA-Info-Request-Form-362.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: firstname.lastname@example.orgSource:The Law Offices of Vincent Wong